Peptides8 min read
Amylin plus GLP-1: when two hormone pathways improve treatment
Human trials show when amylin and GLP-1 activity add weight benefit, why glucose results can differ and why zenagamtide is distinct from CagriSema.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
What Humanin needs before a clinical longevity claim
Humanin has intriguing aging biology, but genetics, biomarkers and animal results leave specific gaps before a clinical longevity claim.
Read article
Peptides9 min read
Epitalon and sleep: what the circadian research actually measured
Human Epitalon research has measured melatonin-related markers and clock genes. Here is why those findings do not yet establish a treatment for insomnia.
Read article
Peptides9 min read
Semax derivatives: why “stronger” needs its own evidence
Acetylated, amidated and other Semax-related products are not interchangeable clinical evidence. Start with chemical identity, then ask what was actually tested.
Read article
Peptides9 min read
Mazdutide and uric acid: a promising blood result is not yet a gout claim
Mazdutide lowered serum urate in obesity trials. The original results support a focused research question, not an established gout-treatment claim.
Read article
Peptides9 min read
Eloralintide and cagrilintide: meaningful differences without a premature winner
The drugs share an amylin starting point but differ in receptor activity and clinical evidence. Separate trials cannot establish a winner.
Read article
Peptides8 min read
What would make petrelintide useful in everyday care?
Published phase 2 findings move petrelintide beyond an early signal. Routine care needs a fuller account of who benefits, what persists and how treatment feels.
Read article
Peptides9 min read
BPC-157's infusion pilot: what two participants can tell us
BPC-157's intravenous pilot followed two previously exposed adults for three days. Its observations leave uncommon, delayed and product-specific risks unresolved.
Read article
Peptides9 min read
Does feeling more energetic show that SS-31 improved mitochondria?
Feeling better, walking farther and producing ATP are different outcomes. Human elamipretide studies show why symptoms cannot identify a mitochondrial mechanism.
Read article
Peptides8 min read
GHRP-2 and growth-hormone deficiency: what treatment studies show
Early pediatric studies suggested a growth response, but a larger randomized trial did not confirm a benefit. Diagnosis and treatment outcomes need separate interpretation.
Read article
Peptides8 min read
Research PT-141 and prescription bremelanotide: what differs?
A shared ingredient name does not establish the same formulation, quality controls, or clinical evidence.
Read article
Peptides9 min read
Oxytocin is not simply the “trust hormone”
Original experiments, failed replications and a positive 2026 study in low-trusting men tell a more specific story than the nickname.
Read article169–180 of 323 articles